{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:03Z","timestamp":1787067723456,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals S.A funded this study"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40264-024-01456-y","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T10:04:55Z","timestamp":1719828295000},"page":"1137-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhanced Safety Surveillance of GSK\u2019s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022\/2023 Influenza Season"],"prefix":"10.1007","volume":"47","author":[{"given":"Ignacio Salamanca","family":"de la Cueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Brotons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falko","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pir\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Talsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Eckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Nikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Martinez","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Alsdurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"1456_CR1","unstructured":"World Health Organization (WHO). Influenza (seasonal). Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal). [Accessed 26 Sep 2023]."},{"issue":"1","key":"1456_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3. https:\/\/doi.org\/10.1038\/s41572-018-0002-y.","journal-title":"Nat Rev Dis Primers"},{"key":"1456_CR3","unstructured":"European Centre for Disease Prevention and Control (ECDC). Factsheet about seasonal influenza. Available from: https:\/\/www.ecdc.europa.eu\/en\/seasonal-influenza\/facts\/factsheet. [Accessed 26 Sep 2023]."},{"issue":"9","key":"1456_CR4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.vaccine.2021.11.080","volume":"40","author":"J Paget","year":"2022","unstructured":"Paget J, Iuliano AD, Taylor RJ, Simonsen L, Viboud C, Spreeuwenberg P, et al. Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project. Vaccine. 2022;40(9):1361\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.080.","journal-title":"Vaccine"},{"issue":"10127","key":"1456_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285\u2013300. https:\/\/doi.org\/10.1016\/S0140-6736(17)33293-2.","journal-title":"Lancet"},{"issue":"41","key":"1456_CR6","doi-asserted-by":"publisher","first-page":"2100975","DOI":"10.2807\/1560-7917.ES.2021.26.41.2100975","volume":"26","author":"A Larrauri","year":"2021","unstructured":"Larrauri A, Trilar KP. Preparing for an influenza season 2021\/22 with a likely co-circulation of influenza virus and SARS-CoV-2. Euro Surveill. 2021;26(41):2100975. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.41.2100975.","journal-title":"Euro Surveill"},{"key":"1456_CR7","unstructured":"World Health Organization. WHO Regional Office for Europe recommendations on influenza vaccination for the 2021\/2022 season during the ongoing COVID-19 pandemic. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/347890\/WHO-EURO-2021-3920-43679-61434-eng.pdf?sequence=1. [Accessed 26 Sep 2023]."},{"issue":"1","key":"1456_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jmwh.13203","volume":"66","author":"C Nypaver","year":"2021","unstructured":"Nypaver C, Dehlinger C, Carter C. Influenza and influenza vaccine: a review. J Midwifery Womens Health. 2021;66(1):45\u201353. https:\/\/doi.org\/10.1111\/jmwh.13203.","journal-title":"J Midwifery Womens Health"},{"issue":"12 Suppl. 2","key":"1456_CR9","doi-asserted-by":"publisher","first-page":"S405","DOI":"10.1093\/infdis\/jiab269","volume":"224","author":"T Becker","year":"2021","unstructured":"Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus ADME. Influenza vaccines: successes and continuing challenges. J Infect Dis. 2021;224(12 Suppl. 2):S405\u201319. https:\/\/doi.org\/10.1093\/infdis\/jiab269.","journal-title":"J Infect Dis"},{"key":"1456_CR10","unstructured":"World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2021\u20132022 northern hemisphere influenza season. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-northern-hemisphere-recommendation-2021-2022\/202102_recommendation.pdf?sfvrsn=2af603d8_12&download=true. [Accessed 26 Sep 2023]."},{"key":"1456_CR11","unstructured":"European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. 2014. EMA\/PRAC\/222346\/2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu_en.pdf. [Accessed 26 Sep 2023]."},{"key":"1456_CR12","unstructured":"European Medicines Agency (EMA). Guideline on influenza vaccines: non-clinical and clinical module. 2016. EMA\/CHMP\/VWP\/457259\/2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/influenza-vaccines-non-clinical-clinical-module_en.pdf. [Accessed 26 Sep 2023]."},{"issue":"4","key":"1456_CR13","doi-asserted-by":"publisher","DOI":"10.2196\/12016","volume":"5","author":"S de Lusignan","year":"2019","unstructured":"de Lusignan S, Correa A, Dos Santos G, Meyer N, Haguinet F, Webb R, et al. Enhanced safety surveillance of influenza vaccines in general practice, winter 2015\u201316: feasibility study. JMIR Public Health Surveill. 2019;5(4): e12016. https:\/\/doi.org\/10.2196\/12016.","journal-title":"JMIR Public Health Surveill"},{"issue":"5","key":"1456_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/21645515.2019.1565258","volume":"15","author":"S de Lusignan","year":"2019","unstructured":"de Lusignan S, Ferreira F, Damaso S, Byford R, Pathirannehelage S, Yeakey A, et al. Enhanced passive surveillance of influenza vaccination in England, 2016\u20132017: an observational study using an adverse events reporting card. Hum Vaccin Immunother. 2019;15(5):1048\u201359. https:\/\/doi.org\/10.1080\/21645515.2019.1565258.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"1456_CR15","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1080\/21645515.2019.1705112","volume":"16","author":"S de Lusignan","year":"2020","unstructured":"de Lusignan S, Damaso S, Ferreira F, Byford R, McGee C, Pathirannehelage S, et al. Brand-specific enhanced safety surveillance of GSK\u2019s Fluarix Tetra seasonal influenza vaccine in England: 2017\/2018 season. Hum Vaccin Immunother. 2020;16(8):1762\u201371. https:\/\/doi.org\/10.1080\/21645515.2019.1705112.","journal-title":"Hum Vaccin Immunother"},{"key":"1456_CR16","unstructured":"Division of AIDS. National Institute of Allergy and Infectious Diseases. National Institutes of Health. US Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Corrected Version 2.1. 2017. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf"},{"key":"1456_CR17","unstructured":"World Health Organization (WHO). Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/331506\/WHO-2019-nCoV-SurveillanceGuidance-2020.6-eng.pdf?sequence=1&isAllowed=y. [Accessed 26 Sep 2023]."},{"key":"1456_CR18","unstructured":"World Health Organization (WHO). WHO COVID-19 case definitions. Updated in Public health surveillance for COVID-19, 22 July 2022. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/360579\/WHO-2019-nCoV-Surveillance-Case-Definition-2022.1-eng.pdf?sequence=1. [Accessed 26 Sep 2023]."},{"key":"1456_CR19","unstructured":"GlaxoSmithKline Biologicals. Fluarix Tetra. Quadrivalent influenza vaccine (split virion, inactivated). 2021. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_SG\/products\/PDF\/Fluarix-tetra\/fluarix_tetra_pi_ipi10a_si_nh_approved_24jul19.pdf. [Accessed 26 Sep 2023]."},{"issue":"3","key":"1456_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13098","volume":"17","author":"GD Santos","year":"2023","unstructured":"Santos GD, Eckermann T, Mart\u00ednez-G\u00f3mez X, Parra J, Nwoji U, Salamanca de la Cueva I. Enhanced safety surveillance of GSK\u2019s quadrivalent seasonal influenza vaccine in Germany and Spain (2021\/2022 season) using an electronic patient-reported outcome system for vaccine safety remote monitoring. Influenza Other Respir Viruses. 2023;17(3): e13098. https:\/\/doi.org\/10.1111\/irv.13098.","journal-title":"Influenza Other Respir Viruses"},{"issue":"12","key":"1456_CR21","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-021-01121-8","volume":"44","author":"I Salamanca de la Cueva","year":"2021","unstructured":"Salamanca de la Cueva I, Cinconze E, Eckermann T, Nwoji U, Godderis L, Lu E, et al. Safety profile of GSK\u2019s inactivated quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain: passive enhanced safety surveillance study for the 2019\/2020 influenza season. Drug Saf. 2021;44(12):1375\u201390. https:\/\/doi.org\/10.1007\/s40264-021-01121-8.","journal-title":"Drug Saf"},{"issue":"1","key":"1456_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40121-021-00571-y","volume":"11","author":"G Dos Santos","year":"2022","unstructured":"Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, et al. Brand-specific enhanced safety surveillance study of GSK\u2019s quadrivalent seasonal influenza vaccine, conducted during the COVID-19 pandemic, in Belgium, Germany and Spain, for the 2020\/21 season. Infect Dis Ther. 2022;11(1):463\u201383. https:\/\/doi.org\/10.1007\/s40121-021-00571-y.","journal-title":"Infect Dis Ther"},{"key":"1456_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/1471-2334-13-343","volume":"13","author":"D Kieninger","year":"2013","unstructured":"Kieninger D, Sheldon E, Lin W-Y, Yu C-J, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged \u226518 years. BMC Infect Dis. 2013;13:343. https:\/\/doi.org\/10.1186\/1471-2334-13-343.","journal-title":"BMC Infect Dis"},{"issue":"26","key":"1456_CR24","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1215817","volume":"369","author":"VK Jain","year":"2013","unstructured":"Jain VK, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, Quiambao BP, et al. Vaccine for prevention of mild and moderate-to severe influenza in children. N Engl J Med. 2013;369(26):2481\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1215817.","journal-title":"N Engl J Med"},{"issue":"5","key":"1456_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S2352-4642(18)30062-2","volume":"2","author":"C Claeys","year":"2018","unstructured":"Claeys C, Zaman K, Dbaibo G, Li P, Izu A, Kosalaraksa P, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6\u201335 months: a multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health. 2018;2(5):338\u201349. https:\/\/doi.org\/10.1016\/S2352-4642(18)30062-2.","journal-title":"Lancet Child Adolesc Health."},{"issue":"1","key":"1456_CR26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1186\/s12889-018-6260-5","volume":"18","author":"S Spila Alegiani","year":"2018","unstructured":"Spila Alegiani S, Alfonsi V, Appelgren EC, Ferrara L, Gallo T, Alicino C, et al. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015\/2016 season. BMC Public Health. 2018;18(1):1401. https:\/\/doi.org\/10.1186\/s12889-018-6260-5.","journal-title":"BMC Public Health"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01456-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01456-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01456-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T19:07:02Z","timestamp":1729105622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01456-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01456-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,29]]},"assertion":[{"value":"4 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GlaxoSmithKline Biologicals S.A funded this study (GlaxoSmithKline [GSK] study identifier: 213829) and was involved in all stages of the study, including analysis of the data. GlaxoSmithKline Biologicals S.A also funded all costs associated with the development and publishing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Carlos Brotons, Ignacio Salamanca, Tamara Eckermann, and Falko Panzer declare that their institution received payment from GSK for the conduct of the study. Xavier Mart\u00ednez\u2010G\u00f3mez declares having received payment or honoraria for lectures, presentations, meetings, or educational events from AstraZeneca and Pfizer. Andrew Hastie, Jean-Yves Pir\u00e7on, Jennifer\u00a0E. Gerber, Vanja Nikic, and Hannah\u00a0Alsdurf were employees of the GSK group of companies. Andrew Hastie, Jean-Yves Pir\u00e7on, and Vanja Nikic possesses stock options in GSK. Paul Talsma was an employee of the GSK group of companies at the time of the study. The authors declare no other financial and non\u2010financial relationships and activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The following ethics committees, institutional review boards, and regulatory authorities were consulted in line with country requirements: Comitt\u00e9 d\u2019Etique hospitalo-facultaire Erasme - Universit\u00e9 Libre de Bruxelles in Belgium (approval received: 15 September, 2022), Ethik-Kommission der Bayerischen Landes\u00e4rztekammer in Germany (approval received: 12 September, 2022), Landes\u00e4rztekammer Baden-W\u00fcrttemberg K\u00f6rperschaft des \u00d6ffentlichen Rechts Ethik-Kommission in Germany (approval received: 2 November, 2022), Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n Biom\u00e9dica de Andaluc\u00eda in Spain (approval received: 4 July, 2022), and Generalitat de Catalunya in Spain (approval received: 25 September, 2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Written informed consent or assent was obtained from all individual participants included in this study or their parent(s), guardian(s), or legally acceptable representative(s) prior to participation in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Anonymized individual participant data and study documents can be requested for further research from\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors participated in the design, implementation, analysis, and interpretation of the study and the development of this manuscript. All authors had full access to the data and approved the final manuscript prior to submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"AlphaRix Tetra, Influsplit Tetra, and Fluarix Tetra are trademarks owned by or licensed to the GSK group of companies.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademark statement"}}]}}